A relapse brings more than a diagnosis — it brings questions about cost, coordination and time. i-Saksham is a joint program by Immuneel and Arogya Finance built to carry that weight, so families can focus on one thing: the possibility of remission.
Relapse & counselling
By the treating oncologistClinical & financial eligibility
Coordinated by i-Saksham coordinatorTreatment & CAR-T infusion
At the treating hospitalFollow-up care
Support continues after infusionNo patient should have to carry that burden alone. i-Saksham is a collaborative patient access program by Immuneel and Arogya Finance, designed to simplify the clinical and financial journey for eligible CAR-T cell therapy patients — from relapse to recovery.
Qartemi is the CAR-T cell therapy at the centre of the i-Saksham program — developed in Europe, manufactured in India, and now made financially accessible.
The only CAR-T product in India developed and approved first in Europe, and later in India.
The only CAR-T in India manufactured on the USFDA-approved CliniMACS Prodigy platform.
The only CAR-T available in India with efficacy and safety outcomes comparable to global CAR-Ts.
A complete access ecosystem offering assistance of up to ₹25 lakh at zero-cost EMI for eligible patients.
A single finance navigator to coordinate your financial assistance.
Every eligible patient moves through the same coordinated pathway — clinically assessed, financially supported, and never handled alone.
Arogya Finance is a healthcare-focused NBFC that structures responsible financing for advanced therapies. The i-Saksham Desk runs a clear, documented eligibility check before any sanction.
Share a few details and a patient navigator will reach out to walk you through eligibility, documentation and next steps — at no cost to you.
All fields are required so we can begin your eligibility check.
An i-Saksham patient navigator will call you within one business day. For anything urgent, call the i-Saksham Help Desk on 1800-2680-118.